ArticleTheranostics2019
Generation of hepatic spheroids using human hepatocyte-derived liver progenitor-like cells for hepatotoxicity screening.
Abstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use.Communications biology · 2022Pooled it
- Next-Generation Hepatocyte Expansion: Bridging Molecular Reprogramming with Multicellular Organoids for Clinical Translation.Stem cell reviews and reports · 2026Review
- Automation of 3D liver spheroid generation and acetaminophen dose-response on the MO:BOT enhances assay robustness and precision.Scientific reports · 2026Article
- Developing chemical reprogramming strategies of non-hepatocytes for liver regeneration.Journal of advanced research · 2026Review
- Multiomics analysis elucidated the role of inflammatory response and bile acid metabolism disturbance in electric shock-induced liver injury in mice.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Article
- Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury.Expert opinion on drug metabolism & toxicology · 2025Review
- Hydrogel-Based Strategies for Liver Tissue Engineering.Chem & bio engineering · 2024Review
- Article
- Genetically Modified Hepatocytes Targeting Bilirubin and Ammonia Metabolism for the Construction of Bioartificial Liver System.Biomaterials research · 2024Article
- A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications.Biomaterials · 2024Review
- Liver three-dimensional cellular models for high-throughput chemical testing.Cell reports methods · 2023Review
- Customizable Microfluidic Origami Liver-on-a-Chip (oLOC).Advanced materials technologies · 2022Article
- Gut Microbiome Alterations and Hepatic Metabolic Flexibility in the Gansu Zokor,Frontiers in cardiovascular medicine · 2022Article
- Development of Biomimetic Hepatic Lobule-Like Constructs on Silk-Collagen Composite Scaffolds for Liver Tissue Engineering.Frontiers in bioengineering and biotechnology · 2022Article
- Three-Dimensional Liver Culture Systems to Maintain Primary Hepatic Properties for Toxicological Analysis In Vitro.International journal of molecular sciences · 2021Review
- Article
- Robust expansion and functional maturation of human hepatoblasts by chemical strategy.Stem cell research & therapy · 2021Article
- A MicroRNA-Based Network Provides Potential Predictive Signatures and Reveals the Crucial Role of PI3K/AKT Signaling for Hepatic Lineage Maturation.Frontiers in cell and developmental biology · 2021Article
- A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies.Frontiers in cell and developmental biology · 2021Review
- The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction.Theranostics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Zhenyu WangDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Weijian LiDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Hongshu JingDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Ming DingDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Gongbo FuInternational Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Tianjie YuanDepartment of Anesthesiology and Critical Care Medicine, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Weijian HuangInternational Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Mengjun DaiDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Dan TangDepartment of Anesthesiology and Critical Care Medicine, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Min ZengCelliver Biotechnology Inc., Shanghai, China.
Yi ChenDepartment of Anesthesiology and Critical Care Medicine, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Hongdan ZhangCelliver Biotechnology Inc., Shanghai, China.
Xuejing ZhuCelliver Biotechnology Inc., Shanghai, China.
Yuan PengDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Qigen LiOrgan Transplantation Center, Changhai Hospital, Second Military Medical University, Shanghai, China.
Wei-Feng YuDepartment of Anesthesiology and Critical Care Medicine, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
He-Xin YanDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Bo ZhaiDepartment of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsApoptosisCell DifferentiationCell ProliferationCells, CulturedChemical and Drug Induced Liver InjuryCytochrome P-450 Enzyme SystemDose-Response Relationship, DrugGene Expression RegulationHepatocytesHep G2 CellsHumansMolecular Targeted TherapySpheroids, CellularToxicity TestsAntineoplastic AgentsCytochrome P-450 Enzyme Systemhepatocyte spheroidHepLPCsheterogeneityidiosyncratic drug-induced liver injuryTKIs.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.